

Mehmet H Kocoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7127738/publications.pdf>

Version: 2024-02-01

16
papers

344
citations

1307594

7
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

746
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>Blood</i> , 2017, 130, 1189-1197.	1.4	169
2	Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. <i>Neuro-Oncology</i> , 2021, 23, 112-121.	1.2	53
3	The Role of Immunotherapy in Multiple Myeloma. <i>Pharmaceuticals</i> , 2016, 9, 3.	3.8	23
4	Refractory postallogeic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab. <i>American Journal of Hematology</i> , 2019, 94, E216-E219.	4.1	23
5	Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 686-689.	5.2	19
6	Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy. <i>Blood</i> , 2022, 140, 152-156.	1.4	17
7	Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 490-490.	1.4	15
8	Newly diagnosed multiple myeloma: current treatment strategies, emerging therapeutic approaches and beyond. <i>Expert Review of Hematology</i> , 2020, 13, 669-686.	2.2	8
9	Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1339-1347.	1.3	6
10	Therapeutic strategies for durable response in plasma cell granulomas in the central nervous system. <i>Annals of Hematology</i> , 2019, 98, 1027-1029.	1.8	5
11	Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review. <i>British Journal of Ophthalmology</i> , 2023, 107, 901-905.	3.9	3
12	Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e716-e729.	0.4	2
13	Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3577-3580.	1.3	1
14	An Unusual Cause of a Pathological Vertebral Fracture: Solitary Plasmacytoma. <i>American Journal of the Medical Sciences</i> , 2020, 360, 206-207.	1.1	0
15	Racial Differences in Molecular Cytogenetic Abnormalities in Black and White Patients with Multiple Myeloma (MM): A Single-Center Experience. <i>Blood</i> , 2015, 126, 1767-1767.	1.4	0
16	Revisiting the Case of Sarah Newbury's Death from Mollities Ossium. <i>Cancer Investigation</i> , 2022, , 1-10.	1.3	0